Subscribe To

Price Alert Latest News Economic Calendar News

BDSX / Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held virtually February 15-17, 2022. BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Date: Wednesday, February 16, 2022 Time: 4:30 PM ET Read More

Demo Live Account See Partner Details

Content Topics

Eqt

Ab

Publ

St

Biodesix

Present

Medtech

Digital

Health

Science

Diagnostic

Conference

Stock

BDSX

Posted: Feb 9 2022, 06:00

Author Name: Business Wire

BDSX News

By Zacks Investment Research
September 8, 2023

Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OI Glass (OI), KE Hodlings (BEKE), Biodesix (BD

By Zacks Investment Research
August 7, 2023

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss

By Seeking Alpha
May 14, 2023

Biodesix, Inc. (BDSX) Q1 2023 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Chris Brinzey - Investor Relations Scott H

By Zacks Investment Research
May 11, 2023

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss

By Zacks Investment Research
March 6, 2023

Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -7.69% and 10.23%, respectively, for the quarter ended December 2022. Do the numbers

By Seeking Alpha
February 13, 2023

Biodesix Appears Poised For 2023 Growth

Biodesix, Inc. published its Q3 financial results on November 3, 2022. The firm provides an array of lung cancer diagnostic tests in the U.S.

By Seeking Alpha
November 6, 2022

Biodesix, Inc. (BDSX) Q3 2022 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Representatives Scott Hutton - Chief Executive Offi

By Seeking Alpha
August 6, 2022

Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2022 Results - Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.